Evotec to Re-engineer Drug Discovery and Development Operations

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

- Evotec to concentrate all proprietary core research
programs at its European operations
- Leveraging world-class Discovery Alliance Business
infrastructure will lead to a minimum of EUR 10 million annual
savings
- US operations will be wound down with immediate effect

Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ:
EVTC) announced today that in the context of its Evotec 2012 - Action
Plan to Focus and Grow, the Company is re-engineering its drug
discovery and development operations to improve efficiency and
realize further cost saving potential.

The continuing strength of a successful Discovery Alliance Business
gives Evotec the unique opportunity to more efficiently leverage its
research and development infrastructure. As a consequence, all Evotec
proprietary programs will be managed through its European operations.
This will lead to a minimum of EUR 10 million annual cost savings
from 2010 onwards. As a consequence, approximately 45 people will
leave the Company, which will bring its workforce to a total of below
330, and the US operations of the Company's subsidiary Renovis, Inc.
in South San Francisco, California will be wound down with immediate
effect.

Dr Werner Lanthaler, Chief Executive Officer of Evotec AG, said: "In
the context of our Evotec 2012 Action Plan to Focus and Grow we have
identified strong synergistic potential in the concentration of our
operations into one seamless process and operation. Through this
re-engineering we will be able to most efficiently advance our
proprietary core projects and deliver world-class drug discovery and
development support to our partners. It also realizes significant
cost savings necessary for optimal shareholder value creation.
Unfortunately, however, it also means that we have to close down our
operations in the United States. I would like to express my sincere
appreciation to all affected employees for their important
contributions to Evotec."

About the Evotec 2012 - Action Plan to Focus and Grow
Evotec has started to implement the Evotec 2012 Action Plan to Focus
and Grow in March 2009. The plan's objective is to ensure that the
Company can extend its cash reach comfortably beyond 2012, further
grow its strong Discovery Alliance Business, reach important
milestones within its development programs, and advance and enhance
its pipeline to demonstrate meaningful value over this period. The
core elements of this plan include actions to strengthen the
Discovery Alliance Business, refocus the pipeline on the most
valuable assets, build strategic alliances on more available projects
and significantly reduce the operating expenses and strategic risks.

Contact Evotec AG:
Dr Werner Lanthaler, Chief Executive Officer, Phone:
+49.(0)40.56081-242, werner.lanthaler@evotec.com
Anne Hennecke, Senior Vice President, Investor Relations & Corporate
Communications, Phone: +49.(0)40.56081-286, anne.hennecke@evotec.com

Forward-Looking Statements
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. Such
forward-looking statements include, but are not limited to,
statements about our expectations and assumptions concerning future
reductions in operating expenses and cash burn, regulatory, clinical
and business strategies, the progress of our clinical development
programs and timing of the results of our clinical trials, strategic
collaborations and management's plans, objectives and strategies.
These statements are neither promises nor guarantees, but are subject
to a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. In
particular, the risks and uncertainties include, among other things:
risks that product candidates may fail in the clinic or may not be
successfully marketed or manufactured; risks relating to our ability
to advance the development of product candidates currently in the
pipeline or in clinical trials; our inability to further identify,
develop and achieve commercial success for new products and
technologies; the risk that competing products may be more
successful; our inability to interest potential partners in our
technologies and products; our inability to achieve commercial
success for our products and technologies; our inability to protect
our intellectual property and the cost of enforcing or defending our
intellectual property rights; our failure to comply with regulations
relating to our products and product candidates, including FDA
requirements; the risk that the FDA may interpret the results of our
studies differently than we have; the risk that clinical trials may
not result in marketable products; the risk that we may be unable to
successfully secure regulatory approval of and market our drug
candidates; and risks of new, changing and competitive technologies
and regulations in the U.S. and internationally.

The list of risks above is not exhaustive. Our most recent Annual
Report on Form 20-F, filed with the Securities and Exchange
Commission, and other documents filed with, or furnished to the
Securities and Exchange Commission, contain additional factors that
could impact our businesses and financial performance. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in
our expectations or any change in events, conditions or circumstances
on which any such statement is based.

--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480; ISIN:
DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All
Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Düsseldorf,
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt
in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.